Latest News
Five Years of Growth and Discovery: MED13L Registry
The MED13L Foundation has completed a five-year analysis of MED13L registry data from Simons Searchlight, led by Ricardo Ramirez, the Foundation’s Chief Scientific Officer. Drawing on 17 quarterly reports from…
Family-Reported NSAID Survey: An Early Signal for Research
In June 2026, the MED13L Foundation surveyed families about their children’s use of NSAIDs, including ibuprofen, following repeated reports of changes that appeared to extend beyond expected effects on fever…
Browse by Topic
Spring 2026 Multi-Language Research Update
A message from Ricardo Ramírez, PhD, Chief Scientific Officer of The MED13L Foundation — with the latest updates on our progress and achievements. Now available! Get the latest update in…
MED13L Foundation Funds UCSF CRISPRa Study for MED13L Haploinsufficiency
Friday, December 5th, 2025 The MED13L Foundation is pleased to announce the execution of a Sponsored Research Agreement with the University of California, San Francisco (UCSF) to support a new…
Brain & Life Magazine: How Families Are Leading the Charge in Rare Disease Advocacy
A recent article in Brain & Life highlights the powerful role of families in rare disease advocacy—including the efforts of MED13L Syndrome parents. The piece showcases how grassroots advocacy drives research and awareness for…
MED13L Foundation to Launch Natural History Study of MED13L Syndrome with Boston Children’s Hospital
As featured in Brain & Life Magazine BOSTON, May 5, 2025 — The MED13L Foundation today announced a nearly $250,000 grant to help launch an innovative natural history study at…
Naproxen Shown to Upregulate MED13L.
One step closer to a therapeutic treatment. Could it be this easy? We Have a Hit! Rarebase Delivers. It’s not a home run, but a solid double from Rarebase! After…
Join us! World MED13L Syndrome Day 2023
Have you been wanting to get involved in the MED13L Foundation? Here is a great way! We are starting to plan for… World MED13L Syndrome Day – 2023 …and we…












